comparemela.com
  1. Home
  2. Live Updates
  3. Anurag Relan - Breaking News

Latest Breaking News On - Anurag relan - Page 4 : comparemela.com

Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH s Blood

/PRNewswire/ Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces today that the positive results of a.

United statesUnited kingdomCity ofNoord hollandEthan metelenisHeather robertsonMichael levitanDan caleyAnurag relanVicki modellVp investor relations corporate communicationsExchange commissionAmerican society of hematologyPharming groupnvPharming groupLifespring life sciences communication

Pharming Group NV: Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH s Blood

Leniolisib was well tolerated and significant improvement over placebo was notable in the co-primary endpoints, reflecting a favorable impact on patients' immune dysregulation and deficiency The

United statesUnited kingdomCity ofNoord hollandEthan metelenisHeather robertsonMichael levitanDan caleyAnurag relanVicki modellVp investor relations corporate communicationsExchange commissionAmerican society of hematologyPrnewswire pharming groupnvPharming groupLifespring life sciences communication

Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib

/PRNewswire/ Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM / Nasdaq: PHAR) announces today that its Marketing Authorisation.

United statesUnited kingdomCity ofNoord hollandEthan metelenisHeather robertsonDan caleyAnurag relanExchange commissionPrnewswire pharming groupnvEuropean medicines agencyPharming groupCommittee for medicinal products human useLifespring life sciences communicationInvestor relations corporate communicationsEuropean economic area

Pharming Group N V : Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib

Marketing authorisation in the European Economic Area anticipated in H1 2023 LEIDEN, Netherlands, Oct. 28, 2022 /PRNewswire/ Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT

United statesUnited kingdomCity ofNoord hollandEthan metelenisHeather robertsonDan caleyAnurag relanExchange commissionPrnewswire pharming groupnvEuropean medicines agencyPharming groupCommittee for medicinal products human useLifespring life sciences communicationInvestor relations corporate communicationsEuropean economic area

Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib

/PRNewswire/ Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has submitted a Marketing.

United statesUnited kingdomCity ofNoord hollandEthan metelenisHeather robertsonAnurag relanExchange commissionPharming groupnv euronext amsterdamPrnewswire pharming groupnvEuropean medicines agencyPharming groupCommittee for medicinal products human useLifespring life sciences communicationInvestor relations corporate communicationsMarketing authorisation application

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.